A Medicare coverage determination is a formal decision by Medicare about whether, and under what conditions, it will pay for a specific item, service, or procedure. Two distinct instruments make these decisions: National Coverage Determinations (NCDs), issued directly by the Centers for Medicare & Medicaid Services (CMS) and binding nationwide, and Local Coverage Determinations (LCDs), issued by regional Medicare Administrative Contractors (MACs) and binding only within that contractor’s jurisdiction. For clinical research administrators, one coverage determination matters more than any other: NCD 310.1, “Routine Costs in Clinical Trials,” which sets the rules for when Medicare will pay for a beneficiary’s routine care while they are enrolled in a clinical trial. Getting the NCD/LCD mechanism right is a prerequisite for the coverage analysis work described in the companion guide on False Claims Act liability in clinical trial billing, since a coverage analysis is only as accurate as the coverage determinations it is built against.
The statutory basis: “reasonable and necessary”
Medicare’s coverage authority traces back to Section 1862(a)(1)(A) of the Social Security Act, which excludes from Medicare payment any items or services that are not “reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member.” Because the statute does not itself define which specific items and services meet that standard, CMS and its contractors issue coverage determinations to apply the reasonable-and-necessary standard to particular technologies, procedures, and clinical circumstances. Absent an applicable NCD or LCD, a Medicare claims processing contractor makes that determination on a claim-by-claim basis.
National Coverage Determinations (NCDs)
An NCD is a nationwide coverage decision issued by CMS itself, applicable to all fifty states and binding on every Medicare Administrative Contractor and every Medicare Advantage plan. CMS develops an NCD either on its own initiative or in response to a formal request — typically from a manufacturer, medical society, or other stakeholder — and the process generally includes a review of the clinical evidence, a public comment period, and, for more complex or contested technologies, a meeting of the Medicare Evidence Development & Coverage Advisory Committee (MEDCAC), an independent panel that advises CMS on the strength of the evidence base. An NCD can grant coverage, deny it, restrict it to specific clinical indications or a registry/coverage-with-evidence-development framework, or leave the determination to local discretion by declining to issue a national policy at all. Once finalized, an NCD supersedes any conflicting LCD; a MAC cannot use an LCD to cover something an NCD excludes, or exclude something an NCD requires be covered.
Local Coverage Determinations (LCDs)
Where no NCD exists, or where an NCD leaves implementation details unaddressed, a Medicare Administrative Contractor may issue an LCD to state, for its own jurisdiction, whether and under what documented clinical circumstances an item or service is reasonable and necessary. MACs are the private contractors CMS engages, on a regional jurisdictional basis, to process Medicare Part A and Part B fee-for-service claims; because each MAC covers a defined multi-state jurisdiction, LCDs can vary from one region of the country to another for the same service, provided none of them contradicts a binding NCD. Before an LCD takes effect, the MAC must publish it in proposed form, accept public comment, and notify its Contractor Advisory Committee, a body of local physicians and other practitioners who provide clinical input on draft policy. LCDs are the more common of the two instruments in day-to-day billing, since CMS issues far fewer NCDs than the volume of billable services in the Medicare fee schedule.
NCD 310.1: routine costs in clinical trials
NCD 310.1, effective July 9, 2007, is the coverage determination that most directly affects clinical research administration. It establishes that Medicare covers the routine costs of a qualifying clinical trial — items and services a beneficiary would have received as part of standard care regardless of trial enrollment, plus items and services otherwise covered by Medicare that happen to be furnished in either arm of the trial. Routine costs specifically exclude the investigational item or service itself, unless that item or service would independently be covered outside the trial context. Medicare separately covers the reasonable and necessary treatment of complications arising from participation in any clinical trial, whether or not it qualifies under NCD 310.1.
A trial qualifies for this routine-costs coverage if its subject or purpose evaluates an item or service that falls within a Medicare benefit category, it has genuine therapeutic intent rather than testing toxicity or disease mechanisms exclusively in healthy subjects, and — for therapeutic-intervention trials — it enrolls patients with the diagnosed condition rather than healthy volunteers. A trial is automatically deemed to satisfy these qualifying criteria if it is funded by NIH, CDC, AHRQ, CMS, the Department of Defense, or the VA, or if it is conducted under an FDA Investigational New Drug (IND) application, including certain IND-exempt drug trials under 21 CFR 312.2(b)(1). Trials that do not meet an automatic deeming category can still qualify by satisfying the underlying criteria directly, though that determination carries more documentation risk than relying on a deeming category.
Why the NCD/LCD mechanism matters for clinical trial billing compliance
A coverage analysis — the line-by-line mapping of every protocol-required visit and procedure to a payer, performed before a trial opens to enrollment — is only as reliable as the coverage determinations it is built against. NCD 310.1 supplies the qualifying-trial framework, but individual items within a protocol (a particular imaging modality, a genetic test, a device) can also be separately governed by their own NCD or, more often, by an LCD specific to the MAC jurisdiction where the institution bills. A coverage analysis that correctly applies NCD 310.1’s qualifying-trial test but overlooks an applicable LCD for a specific procedure can still misroute a claim. This is the mechanism underlying the billing-compliance exposure described in False Claims Act liability in clinical trial billing: an inaccurate or outdated coverage determination read against a protocol is what produces the double-billing fact pattern behind real False Claims Act settlements, not the science or informed-consent process of the trial itself.
Finding and using coverage determinations
CMS publishes both NCDs and LCDs, along with related coding and billing articles, in the Medicare Coverage Database (MCD), a free, searchable repository at cms.gov that lists determinations by keyword, CPT/HCPCS code, and MAC jurisdiction. Research billing compliance staff performing a coverage analysis should check the MCD for both the applicable NCD and any jurisdiction-specific LCD before finalizing a payer assignment, since an LCD can be updated or retired independently of the underlying NCD, and jurisdictional boundaries or LCD content can differ from what a coverage analysis assumed when the trial first opened.
Reconsideration and appeal
A stakeholder who disagrees with an NCD may request that CMS reconsider it, triggering a review process similar to the original NCD development process, including a new public comment period; a completed NCD is not, however, subject to appeal through the standard Medicare claims-appeals process available to an individual denied claim. LCDs can be challenged in two ways: a stakeholder may request reconsideration directly from the MAC that issued it, and a Medicare beneficiary (or a provider acting on a beneficiary’s behalf) who is denied coverage based on an LCD may challenge that specific LCD’s validity through the standard Medicare claims appeals process, up to and including a hearing before an Administrative Law Judge.
Frequently asked questions
What is the difference between a National Coverage Determination and a Local Coverage Determination?
An NCD is issued directly by CMS and applies nationwide to every Medicare Administrative Contractor and Medicare Advantage plan. An LCD is issued by an individual Medicare Administrative Contractor and applies only within that contractor’s regional jurisdiction. An LCD cannot contradict a binding NCD; MACs issue LCDs to fill gaps where no NCD exists or to add jurisdiction-specific implementation detail.
Who issues Local Coverage Determinations?
Medicare Administrative Contractors (MACs) — the private contractors CMS engages on a regional basis to process Medicare Part A and Part B fee-for-service claims — issue LCDs for their own jurisdictions, after publishing a proposed LCD, taking public comment, and consulting their Contractor Advisory Committee of local clinicians.
What is NCD 310.1 and how does it affect clinical trials?
NCD 310.1, “Routine Costs in Clinical Trials,” is the CMS coverage determination that governs whether Medicare pays for a beneficiary’s routine care costs while enrolled in a clinical trial. It covers routine costs of a qualifying clinical trial — defined by a therapeutic-intent test and a set of automatic deeming criteria including NIH, CDC, AHRQ, CMS, DoD, or VA funding, or conduct under an FDA IND — but excludes the investigational item or service itself.
Can a Local Coverage Determination conflict with a National Coverage Determination?
No. An LCD cannot cover something an NCD excludes, or exclude something an NCD requires be covered. Where an NCD exists and addresses a given item or service, it controls; LCDs operate only in the space an NCD leaves open or undefined.
Where can research billing compliance staff find current coverage determinations?
The Medicare Coverage Database (MCD), a free CMS-maintained repository searchable by keyword, CPT/HCPCS code, and MAC jurisdiction, is the authoritative source for both current NCDs and LCDs, including their effective dates and any pending reconsiderations.
How does the NCD/LCD mechanism relate to False Claims Act risk in clinical trial billing?
A coverage analysis has to be built against the correct, current NCDs and LCDs for every protocol item, not just NCD 310.1’s qualifying-trial test. An LCD that changes after a coverage analysis was completed, or a jurisdiction-specific LCD that was never checked, is a realistic root cause of the payer-misrouting fact pattern described in the companion guide on False Claims Act liability in clinical trial billing.
